Pegargiminase Emerging Drug Insight and Market Forecast - 2032

“"Pegargiminase Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about pegargiminase for malignant pleural mesothelioma (MPM) in the seven major markets. A detailed picture of the pegargiminase for MPM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the pegargiminase for MPM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the pegargiminase market forecast analysis for MPM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in MPM.

Drug Summary:

Pegargiminase (ADI-PEG 20), a degrading arginine enzyme, is a product of Polaris Pharmaceuticals currently being investigated in the ATOMIC-Meso Phase II/III study (NCT02709512) clinical study. Pegargiminase is administered by intramuscular injection, depleting the external supply of an amino acid called arginine. The External supply of arginine is critical for the survival of mesothelioma cell lines deficient with an enzyme called ASS1. Depleting the external supply of arginine will lead to the death of cancer cells that are arginine-dependent while leaving the patient's normal cells unharmed and may block the growth of cancer cells that need arginine. Pegargiminase is being developed with pemetrexed and cisplatin to treat advanced MPM patients with low ASS1 expression.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the pegargiminase description, mechanism of action, dosage and administration, research and development activities in malignant pleural mesothelioma (MPM).
• Elaborated details on pegargiminase regulatory milestones and other development activities have been provided in this report.
• The report also highlights the pegargiminase research and development activities in MPM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around pegargiminase.
• The report contains forecasted sales of pegargiminase for MPM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for MPM.
• The report also features the SWOT analysis with analyst views for pegargiminase in MPM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Pegargiminase Analytical Perspective by DelveInsight

• In-depth Pegargiminase Market Assessment

This report provides a detailed market assessment of pegargiminase for malignant pleural mesothelioma (MPM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• Pegargiminase Clinical Assessment

The report provides the clinical trials information of pegargiminase for MPM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for malignant pleural mesothelioma (MPM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence pegargiminase dominance.
• Other emerging products for MPM are expected to give tough market competition to pegargiminase and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of pegargiminase in MPM.
• Our in-depth analysis of the forecasted sales data of pegargiminase from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the pegargiminase in MPM.

Key Questions

• What is the product type, route of administration and mechanism of action of pegargiminase?
• What is the clinical trial status of the study related to pegargiminase in malignant pleural mesothelioma (MPM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the pegargiminase development?
• What are the key designations that have been granted to pegargiminase for MPM?
• What is the forecasted market scenario of pegargiminase for MPM?
• What are the forecasted sales of pegargiminase in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to pegargiminase for MPM?
• Which are the late-stage emerging therapies under development for the treatment of MPM?